Currently out of the existing stock ratings of Mayank Mamtani, 320 are a BUY (90.4%), 29 are a HOLD (8.19%), 5 are a SELL (1.41%).

Mayank Mamtani

Work Performance Price Targets & Ratings Chart

Analyst Mayank Mamtani, currently employed at B. RILEY, carries an average stock price target met ratio of 33.39% that have a potential upside of 56.22% achieved within 181 days.

Mayank Mamtani’s has documented 659 price targets and ratings displayed on 54 stocks. The coverage is on Healthcare, Industrials, Consumer Cyclical sectors.

Most recent stock forecast was given on TRVI, Trevi Therapeutics at 20-Jul-2026.

Wall Street Analyst Mayank Mamtani

Analyst best performing recommendations are on ARQL (ARQULE).
The best stock recommendation documented was for ARQL (ARQULE) at 11/27/2019. The price target of $14 was fulfilled within 12 days with a profit of $4.24 (43.44%) receiving and performance score of 36.2.

Average potential price target upside

of $72.78 (85.94%) on NVAX (NOVAVAX).
of $58.25 (37.29%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $35.44 (76.63%) on FBIO (FORTRESS BIOTECH).

ACST Acasti Pharma ALNA Allena Pharmaceuticals ALT Altimmune ARCT Arcturus Therapeutics Holdings ARWR Arrowhead Pharmaceuticals BIVI Biovie DRNA Dicerna Pharmaceuticals ELOX Eloxx Pharmaceuticals FREQ Frequency Therapeutics GANX Gain Therapeutics ICPT Intercept Pharmaceuticals MDGL Madrigal Pharmaceuticals NGM NGM Biopharmaceuticals NVAX Novavax SAVA Cassava Sciences SEEL Seelos Therapeutics TFFP Tff Pharmaceuticals TGTX TG Therapeutics VXRT Vaxart HTBX Heat Biologics MBIO Mustang Bio SPPI Spectrum Pharmaceuticals ABUS Arbutus Biopharma Corp CBAY Cymabay Therapeu INMB INmune Bio AGEN Agenus XFOR X4 Pharmaceuticals CGTX Cognition Therapeutics GLMD Galmed Pharmaceuticals Ltd NHWK Nighthawk Biosciences VKTX Viking Therapeutics CYTK Cytokinetics GRTS Gritstone Oncology TRVI Trevi Therapeutics ARQL ArQule DRRX Durect GALT Galectin Therapeutics IMV IMV MDCO The Medicines Company DNLI Denali Therapeutics HROW Harrow Health MGNX MacroGenics NKTR Nektar Therapeutics CNTA Centessa Pharmaceuticals PLC ADR ZYME Zymeworks Common Stock AL Air Lease FBIO Fortress Biotech LCTX Lineage Cell Therapeutics SA Seabridge Gold SCLX Scilex Holding Company SEE Sealed Air TBPH Theravance Biopharma FR First Industrial Realty Trust PDSB PDS Biotechnology Corp

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Oren Livnat (HC WAINWRIGHT)